Drug development and new therapies
"We research in those therapeutic areas that can provide new pharmacological treatments for our patients."
DRA. LUCÍA VANRELL
DIRECTOR OF TRANSLATION AND INNOVATION
We are advancing in the knowledge of new therapeutic strategies
From discovery to actual application in the treatment of patients' diseases, our research culminates in the development of new therapies, drugs and diagnostic tools.
-
FOXP3. Inhibitors of FOXP3 Transcription Factor for cancer therapy
Target: Disruption of FOXP3 dimerizationImmunoregulatory function of T regulatory cells (Treg) may hinder the induction of immune responses against cancer and infectious agents.
FOXP3 transcription factor is essential for the specification and maintenance of Treg cells and it is considered its “master regulator”.
- Keywords:
- Inmunoterapia ,
- Cáncer ,
- Inmunorregulación
- Early Discovery
- Discovery
- Preclinical
- Clinical
- Diagnostics
-
Cancer ViroTherapy. Semliki Forest Virus: An efficient self-replicative RNA vector for cancer therapy
Target: Inmune responseCombination of immunotherapy and virotherapy, using oncolytic viruses, has shown great promise in cancer therapy.
Semliki Forest virus (SFV) vectors are based on a self-replicating RNA that constitutes a promising tool for cancer therapy due to several intrinsic properties that include high expression levels, induction of type I interferon (IFN) responses and apoptosis in tumor cells.
SFV vectors able to express immunostimulatory proteins, such as interleukin-12 (IL-12) or IFNα, have been developed.
- Keywords:
- Inmunoterapia ,
- Cáncer ,
- Virus Oncolíticos ,
- Semliki Forest Virus
- Early Discovery
- Discovery
- Preclinical
- Clinical
- Diagnostics
-
Glypican 3 specific T cell receptors for adoptive T cell therapy
Target: GPC3 (Glypican 3)- Introduction:
Identification of different TCR clonotypes specific for an HLA-A2-restricted epitope of GPC3. Cloning and application of these TCRs in the treatment of hepatocarcinoma.
- Results:
The developed TCRs recognize and eliminate HLA-A2+GPC3+ tumor cells and have great potential for engineering the patient's autologous T cells to treat GPC3+ tumors.
- Keywords:
- Cáncer ,
- Terapia celular ,
- Hepatocarcinoma
- Early Discovery
- Discovery
- Preclinical
- Clinical
- Diagnostics
- Introduction:
-
CM-1315-P60. Inhibitors of FOXP3 transcription factor for cancer therapy
Target: Disruption of FOXP3 dimerization- Introduction:
Identification of P60 peptide and P60-derived peptides as novel agents for tumor immunotherapy capable of inhibiting FOXP3 homodimerization and FOXP3/AML1 interaction.
- Results:
P60/P60 peptides affect the immunosuppressive activity of Treg cells, increase T cell proliferation and cytokine production after TCR stimulation and exert antitumoral effects in vivo in tumor murine models.
- Keywords:
- Cáncer ,
- Infecciones crónicas virales ,
- Inmunoterapia ,
- Inmunorregulación
- Early Discovery
- Discovery
- Preclinical
- Clinical
- Diagnostics
- Introduction:
